Zacks Investment Research upgraded shares of Ocular Therapeutix (NASDAQ:OCUL) from a sell rating to a hold rating in a research note released on Tuesday.

According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. “

Other equities analysts have also recently issued reports about the stock. HC Wainwright set a $10.00 price objective on shares of Ocular Therapeutix and gave the stock a buy rating in a research report on Wednesday, October 10th. BidaskClub cut shares of Ocular Therapeutix from a hold rating to a sell rating in a research report on Tuesday, October 9th. Raymond James assumed coverage on shares of Ocular Therapeutix in a research report on Wednesday, November 14th. They set a strong-buy rating and a $10.00 price objective on the stock. ValuEngine upgraded shares of Ocular Therapeutix from a sell rating to a hold rating in a research report on Wednesday, January 2nd. Finally, JMP Securities reiterated a buy rating and set a $9.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, October 11th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Ocular Therapeutix has an average rating of Buy and a consensus target price of $12.38.

NASDAQ OCUL opened at $3.51 on Tuesday. The firm has a market capitalization of $148.61 million, a price-to-earnings ratio of -1.60 and a beta of 1.84. Ocular Therapeutix has a 1 year low of $3.46 and a 1 year high of $8.28. The company has a current ratio of 4.35, a quick ratio of 4.34 and a debt-to-equity ratio of 0.18.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.02). Ocular Therapeutix had a negative net margin of 2,822.15% and a negative return on equity of 133.73%. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, analysts anticipate that Ocular Therapeutix will post -1.55 EPS for the current year.

In other news, insider Kevin F. Hanley acquired 10,000 shares of the stock in a transaction on Monday, December 10th. The shares were purchased at an average cost of $5.60 per share, for a total transaction of $56,000.00. Following the transaction, the insider now owns 10,000 shares in the company, valued at approximately $56,000. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Daniel M. Bollag acquired 17,400 shares of the stock in a transaction on Thursday, December 6th. The shares were purchased at an average price of $5.76 per share, for a total transaction of $100,224.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 37,400 shares of company stock worth $211,224. Corporate insiders own 15.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of OCUL. JGP Global Gestao de Recursos Ltda. purchased a new position in shares of Ocular Therapeutix during the 4th quarter valued at $50,000. Trexquant Investment LP purchased a new position in shares of Ocular Therapeutix during the 3rd quarter valued at $139,000. Rhumbline Advisers grew its holdings in shares of Ocular Therapeutix by 50.3% during the 4th quarter. Rhumbline Advisers now owns 43,465 shares of the biopharmaceutical company’s stock valued at $173,000 after acquiring an additional 14,551 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Ocular Therapeutix during the 3rd quarter valued at $200,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Ocular Therapeutix by 37.0% during the 3rd quarter. Wells Fargo & Company MN now owns 45,046 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 12,170 shares in the last quarter. Institutional investors and hedge funds own 52.31% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

Featured Article: 12b-1 Fees

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.